Kidney Patients Expand Impact on R & D – QNT Press Release

[ad_1]

Largest Patient Meeting Showcases Role September 21-23, 2022

Patient Insight Data Shapes New Generation of Drugs, Devices, and Diagnostics

WASHINGTON, Sept. 19, 2022 /PRNewswire/ — One of the most medically vulnerable populations in America, people living with kidney diseases, is rewriting the book on scientific research and medical innovation by aggressively expanding their impact on basic research, applied research, and the key regulatory and payment deliberations that determine when safe, new products reach the market. Kidney patients have support from a growing national and global alliance of research professionals, kidney medicine experts, elected and career government officials, and private industry executives and investors who respect patients and view their insights and advocacy as the catalysts driving long-overdue cures for kidney diseases and transformations in kidney health.

The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the US, has expanded patient impact on kidney research and development by organizing and training patients to engage effectively with leaders in science and innovation. AAKP is a staunch advocate for patient care choice, independence, and new treatments that allow patients to fully pursue their aspirations, including part-time or full-time work. AAKP will highlight some of the key research and development activities kidney patients are involved in at its Annual National Patient Meeting, being held virtually September 21-23free of charge to all registrants (). Speakers at the meeting include some of the top kidney research and innovation experts, federal officials, and national patient experts.

AAKP founded its Center for Patient Education and Research in 2016 to serve as a rapid fulfillment hub for government, academic, medical device manufacturers, and pharmaceutical industry requests to engage kidney patient experts. The Center also supports AAKP’s efforts to speed the utilization of unique patient insight data across both the product development lifecycle and within regulatory and payment decisions, including those made by commercial insurers (read now). Since its launch, AAKP has dramatically expanded its membership databases, social media recruitment, and analytics tools. The organization now services dozens of requests every year for clinical trial awareness and recruitment campaigns, patient advisory boards, technical evaluation panels, focus groups, patient surveys, clinical research, and public policy research. AAKP leaders and staff provide expert advice to organizations and companies on how to work meaningfully with patients as co-investigators and partners and offer online training for patients on how to be equally effective collaborators.

“AAKP patient members have near unlimited opportunities to impact science and…

Full story available on Benzinga.com

[ad_2]

Source link